In a recent study BoneView helped hospitals reduce missed fractures by 29% and increased sensitivity by 30% for exams with more than one fracture. This is the first solution to receive FDA and CE clearance in this category. In March 2022 the FDA cleared Gleamer's BoneView® AI software to detect fractures and traumatic skeletal injuries in the US. Cleveland Clinic’s is combining PathAI’s AI-based platforms with its clinical expertise and multi-modal data to unlock a broad implementation of next-generation pathology diagnostics. Roche is integrating a novel algorithm developed by PathAI into its digital pathology workflow software and GlaxoSmithKline is leveraging PathAI’s technologies in digital pathology including the use of PathAI’s AIM-NASH tool.

PathAI is collaborating with Bristol Myers Squibb to expand the use of these machine learning models. Researchers engaged in exploratory and clinical drug development research can leverage this platform specifically for regulated clinical trials or translational research. PathAI has also developed AISight to support AI-driven research at biopharma companies, contract researchers, and academic institutions. AISight Dx is a standalone viewer that can interoperate with existing manual and digital pathology workflows and can enable pathologists who are working remotely to collaborate seamlessly to drive fast turnaround times for patients. AISight Dx was designed using input from hundreds of external pathologists in laboratories worldwide as well as from staff at PathAI Diagnostics, PathAI’s anatomic pathology lab. On Augthe FDA cleared PathAI's AISight Dx digital pathology platform for primary diagnosis in clinical settings. With this new AI based biomarker test, patients will have their results in less than one hour. This marks a major milestone in the deployment of Janssen’s AI technology in a clinical setting to efficiently detect biomarkers. In June 2022 Paige announced that in collaboration with Janssen they will deploy a new AI based biomarker test for advanced bladder cancer in a clinical setting. A study conducted by Paige showed that providing this additional information to pathologists during their diagnosis allows pathologists to reduce their false negatives by 70%, reduce their false positives by 24% and likely improve turnaround time of the results back to the urologist and patient. Paige compares tissue patterns in a prostate needle core biopsy to a large database of known cancers and provides information about matches to the pathologist to be used during the pathologist’s diagnosis. In September 2021 in a historic milestone, the FDA cleared Paige Prostate, the first ever AI-based pathology product approved for clinical use. Paige Prostate is the first and only AI-based pathology product to receive FDA clearance for in vitro diagnostic use in detecting cancer in prostate biopsies.

Milestone device list